Clinical value of the <i>MGMT</i> promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment.

ABSTRACT:

Background

Diffuse IDH mutant low-grade gliomas (IDHmt LGG) (World Health Organization grade 2) typically affect young adults. The outcome is variable, with survival ranging from 5 to over 20 years. The timing and choice of initial treatments after surgery remain controversial. In particular, radiotherapy is associated with early and late cognitive toxicity. Over 90% of IDHmt LGG exhibit some degree of promoter methylation of the repair gene O(6)-methylguanine-DNA methytransferase (MGMTp) that when expressed blunts the effect of alkylating agent chemotherapy, for example, temozolomide (TMZ). However, the clinical value of MGMTp methylation predicting benefit from TMZ in IDHmt LGG is unclear.

Methods

Patients treated in the EORTC-22033 phase III trial comparing

SUBMITTER: Darlix A 

PROVIDER: S-EPMC11877643 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature